Risk of bleeding related to antithrombotic treatment in cardiovascular disease

Area of Science:

• Cardiology
• Pharmacology

Background:

• Antithrombotic therapy is essential for cardiovascular disease (CVD) management.
• Bleeding is the most significant complication associated with antithrombotic treatments.
• Understanding bleeding risks across different antithrombotic drug combinations is critical.

Purpose of the Study:

• To review and compare bleeding risks associated with various antithrombotic drug combinations.
• To evaluate risk assessment schemes and bleeding definitions in cardiovascular disease.
• To provide guidance on antithrombotic therapy selection for specific cardiovascular conditions.

Main Methods:

• Literature review of antithrombotic therapy in acute coronary syndrome (ACS), atrial fibrillation (AF), cerebrovascular disease (CVD), and peripheral arterial disease (PAD).
• Comparison of different bleeding risk assessment tools, including HAS-BLED score.
• Analysis of current guidelines for dual antiplatelet therapy (DAPT) and anticoagulation.

Main Results:

• The HAS-BLED score is recommended for AF and ACS patients with AF.
• Dual antiplatelet therapy (P2Y12 inhibitor and aspirin) is recommended for 12 months in ACS patients, preferably with prasugrel or ticagrelor.
• Warfarin is recommended for moderate-to-high stroke risk in AF, with newer agents emerging.
• Clopidogrel is recommended for secondary prevention in CVD; aspirin or clopidogrel for PAD.

Conclusions:

• Individualized antithrombotic therapy is warranted, balancing thromboembolic risk and bleeding.
• Emerging antithrombotic drugs and regimens require careful consideration for optimal patient management.
• Future focus should be on tailoring therapy to minimize bleeding while maximizing efficacy.